Search results
Showing 181 to 185 of 185 results for advanced breast cancer
NICE approves routine use of drug combination for advanced breast cancer
A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
Further treatment option for triple-negative breast cancer recommended
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.